Literature DB >> 24217184

Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.

Jun Ho Yi1, Hyunki Kim, Minkyu Jung, Sang Joon Shin, Jin Sub Choi, Gi-Hong Choi, Seung Hyuk Baik, Byung Soh Min, Nam Kyu Kim, Joong Bae Ahn.   

Abstract

BACKGROUND: Converting chemotherapy followed by surgery is known to be associated with improved clinical outcomes in colorectal cancer (CRC) patients with hepatic metastasis. This study is to investigate the clinicopathological prognostic factors for disease-free survival (DFS) after curative resection of primary and metastatic lesions.
METHODS: We retrospectively analyzed the medical records of 76 CRC patients who had initially had unresectable hepatic metastasis, which was considered resectable after systemic chemotherapy, and had undergone curative surgery in the period from January 2006 to December 2011. DFS was compared by assessing clinical data including age, sex, staging, number of hepatic lesion(s), size of the largest hepatic lesion and serum carcinoembryonic antigen (CEA) levels.
RESULTS: The median age was 57 years and 47 patients were male. The median DFS was 10.4 months. Multivariate Cox regression analysis revealed that age <50 years (HR 2.70, 95% CI 1.43-5.10, p = 0.002) and CEA elevation after curative surgery (HR 2.20, 95% CI 1.11-4.36, p = 0.023) were associated with a shorter DFS.
CONCLUSIONS: Given that patients <50 years old or with elevated CEA levels after curative surgery demonstrated a short DFS, additional postoperative systemic treatment or active surveillance, at least, should strongly be considered for this group.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217184     DOI: 10.1159/000355475

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases.

Authors:  Hiromitsu Hayashi; Toru Beppu; Yasuo Sakamoto; Yuji Miyamoto; Naomi Yokoyama; Takaaki Higashi; Hidetoshi Nitta; Daisuke Hashimoto; Akira Chikamoto; Hideo Baba
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis.

Authors:  Koichi Suzuki; Yuta Muto; Kosuke Ichida; Taro Fukui; Yuji Takayama; Nao Kakizawa; Takaharu Kato; Fumi Hasegawa; Fumiaki Watanabe; Yuji Kaneda; Rina Kikukawa; Masaaki Saito; Shingo Tsujinaka; Kazushige Futsuhara; Osamu Takata; Hiroshi Noda; Yasuyuki Miyakura; Hirokazu Kiyozaki; Fumio Konishi; Toshiki Rikiyama
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

3.  Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.

Authors:  R Mirnezami; A M Mehta; K Chandrakumaran; T Cecil; B J Moran; N Carr; V J Verwaal; F Mohamed; A H Mirnezami
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.